0001386301
false
0001386301
2023-09-15
2023-09-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
September
15, 2023
Date of Report (Date of earliest event reported)
Research Solutions, Inc.
(Exact name of registrant as specified in its charter)
Nevada |
|
1-39256 |
|
11-3797644 |
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
of incorporation) |
|
File Number) |
|
Identification No.) |
N/A
(Address of principal executive offices)
(310) 477-0354
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common stock, $0.001 par value |
RSSS |
The Nasdaq Stock Market LLC |
Indicate by
check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
Item 1.01 Entry into a Material Definitive
Agreement.
On September 15, 2023, Research
Solutions, Inc. (the “Company”) entered into a Cooperation Agreement (the “Cooperation Agreement”) with Peter
Derycz, Bristol Investment Fund, Ltd., Bristol Capital Advisors, LLC and Paul Kessler (collectively, the “Investor Group”).
Pursuant to the Cooperation
Agreement, Mr. Derycz’s employment will be terminated without cause, and he will resign from the Company’s Board of Directors
(the “Board”), any committees thereof on which he serves and any other positions that he holds with the Company and any of
its subsidiaries. The Company agreed to identify and appoint an independent director, to be mutually agreed upon by the Board and the
Investor Group, to fill the resulting vacancy.
Pursuant to the Cooperation
Agreement, the Investor Group irrevocably withdrew its notice of intent to nominate candidates for election to the Board at the Company’s
2023 annual meeting of shareholders (the “Annual Meeting”) and agreed to cease all solicitations of proxies in connection
with the Annual Meeting.
During the term of the Cooperation
Agreement, the Investor Group has agreed to vote all shares of Common Stock beneficially owned by it at all meetings of the Company’s
shareholders in accordance with the Board’s recommendations, except that the Investor Group may vote in its discretion on Extraordinary
Transactions (as defined in the Cooperation Agreement) and, other than with respect to director election, removal or replacement proposals,
in accordance with the recommendations of Institutional Shareholder Services Inc. and Glass, Lewis & Co., LLC if both of them recommend
differently from the Board.
The Investor Group has also
agreed to certain customary standstill provisions prohibiting it from, among other things, (a) acquiring ownership of any securities of
the Company; (b) soliciting proxies; (c) advising or knowingly encouraging any person with respect to the voting or disposition of any
securities of the Company, subject to limited exceptions; and (d) taking actions to change or influence the Board, management or the direction
of certain Company matters. The Company and the Investor Group have agreed to a general mutual release of each other with respect to claims
arising on or prior to and including the date of the Cooperation Agreement. During the term of the Cooperation Agreement, the Company
and the Investor Group have also agreed not to disparage each other or initiate litigation against each other.
The Cooperation Agreement
will terminate on the date that is earlier of (a) thirty days after the conclusion of the Company’s 2024 annual meeting of shareholders
and (b) December 30, 2024. Each of the Company and the Investor Group has the right to terminate the Cooperation Agreement earlier if
the other party commits a material breach of the Cooperation Agreement and such breach (if capable of being cured) is not cured within
15 days after receipt of written notice from the other party specifying such material breach.
The description of the Cooperation
Agreement contained in this Current Report on Form 8-K is a summary and is qualified in its entirety by reference to Exhibit 10.1, which
is incorporated herein by reference.
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On September 15, 2023, in
accordance with the terms of Mr. Derycz’s employment agreement and the Cooperation Agreement, the Company terminated Mr. Derycz’s
employment as Executive Chairman of the Board without cause. Mr. Derycz’s termination resulted in the resignation of Mr. Derycz
from the Board and from all committees on which he served effective as of September 15, 2023.
Item 8.01 Other Events.
On September 18, 2023, the
Company issued a press release announcing the entry into the Cooperation Agreement. A copy of the press release is attached as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements
and Exhibits.
(d) Exhibits.
Exhibit
Number |
|
Description |
10.1* |
|
Cooperation Agreement, dated as of September 15, 2023, by and among Research Solutions, Inc., Peter Derycz, Bristol Investment Fund, Ltd., Bristol Capital Advisors, LLC and Paul Kessler. |
99.1 |
|
Press Release issued September 18, 2023 entitled “Research Solutions Announces Cooperation Agreement with Peter Derycz and Bristol Investment Fund, Ltd.”. |
104 |
|
Cover Page Interactive Data File (embedded as Inline XBRL document) |
* Certain portions
of this exhibit have been redacted pursuant to Item 601(b)(10) of Regulation S-K.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
RESEARCH SOLUTIONS, INC. |
|
|
|
|
Date: September 20, 2023 |
By: |
/s/ William Nurthen |
|
|
William Nurthen |
|
|
Chief Financial Officer |
Exhibit 10.1
Certain identified information has been excluded from this exhibit pursuant to Item 601(b)(10) of
Regulation S-K because it is both not material and would likely cause competitive harm if publicly disclosed. Information that was omitted
has been noted with a placeholder identified by the mark “[***]”
COOPERATION AGREEMENT
This Cooperation Agreement
(this “Agreement”), effective as of September 15, 2023 (the “Effective Date”), is entered
into by and among Research Solutions, Inc., a Nevada corporation (the “Company”), on the one hand, and Peter
Derycz, Bristol Investment Fund, Ltd., Bristol Capital Advisors, LLC and Paul Kessler (collectively, the “Investor Group”),
on the other hand. The Company and the Investor Group are together referred to herein as the “Parties,” and each of
the Company and the Investor Group, respectively, a “Party.” Unless otherwise defined herein, capitalized terms shall
have the meanings given to them in Section 18 herein.
WHEREAS,
as of the Effective Date, the Investor Group beneficially owns an aggregate of 5,921,930 shares of common stock, par value $0.001 per
share, of the Company (the “Common Stock”);
WHEREAS,
on August 16, 2023, Mr. Derycz delivered a notice to the Company (the “Notice”) of his intent to nominate
certain individuals for election to the Company’s board of directors (the “Board”) at the Company’s 2023
annual meeting of stockholders (including, without limitation, any adjournments or postponements thereof and any meeting which may be
called in lieu thereof, the “2023 Annual Meeting”); and
WHEREAS,
the Company and the Investor Group desire to enter into this Agreement regarding compositional changes to the Board and certain other
matters, as provided in this Agreement.
NOW,
THEREFORE, in consideration of the promises, representations and mutual covenants and agreements set forth herein, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:
1. Board
Composition and Other Company Matters.
(a) New
Director.
(i) Effective
as of the Effective Date, the Board, and all applicable committees of the Board, shall take all necessary actions to terminate Mr. Derycz’s
employment without Cause (as such term is defined in that certain Amended and Restated Executive Employment Agreement, dated as of March 29,
2021, between the Company and Mr. Derycz (the “Employment Agreement”)), resulting in the resignation of Mr. Derycz
from the Board and any committees thereof on which he serves, and from any positions that he holds with the Company and any of the subsidiaries
of the Company as of the Effective Date in accordance with the terms of the Employment Agreement.
(ii) As
soon as reasonably practicable following the Effective Date, the Board, and all applicable committees of the Board, shall take all necessary
actions to identify and appoint one (1) new director (the “New Director”) to the Board to fill the vacancy following
and resulting from Mr. Derycz’s departure from the Board, exclusive of any vacancies on any committees of the Board on which
Mr. Derycz had served immediately prior to his departure. Prior to any such appointment, the New Director shall be mutually agreed
upon by the Board and the Investor Group, each cooperating in good faith, and shall be independent of and not be an Affiliate or Associate
of the Investor Group.
(iii) The
Board, and all applicable committees of the Board, shall take all necessary actions to nominate the New Director as a candidate for election
to the Board at the 2023 Annual Meeting, to be held no later than November 14, 2023, with a term expiring at the Company’s
2024 annual meeting of stockholders (the “2024 Annual Meeting”). The Company shall recommend, support and solicit
proxies for the election of the New Director at the 2023 Annual Meeting in a manner no less rigorous and favorable than the manner in
which the Company supports the Board’s other nominees in the aggregate.
(iv) Prior
to the appointment of the New Director, the Board shall determine whether the New Director is an “Independent Director,”
as defined in The Nasdaq Stock Market LLC (the “Nasdaq Stock Market”) Listing Rule 5605 (or applicable requirement
of such other national securities exchange designated as the primary market on which the Common Stock is listed for trading). In connection
with the foregoing, and as a condition to the appointment of the New Director to the Board, the New Director shall (A) provide (x) such
information required to be or customarily disclosed by directors or director candidates in proxy statements or other filings under applicable
law or stock exchange regulations, (y) such information reasonably requested by the Board in connection with assessing eligibility,
independence, and other criteria applicable to directors or satisfying compliance and legal obligations and (z) a fully completed
and executed copy of the Company’s director candidate questionnaire (substantially in the form completed by the Company’s
incumbent non-management directors), in each case, as promptly as practicable to enable the timely filing of the Company’s proxy
statement and other periodic reports with the Securities and Exchange Commission (the “SEC”) and (B) have participated
in customary procedures for new director candidates, including, without limitation, an appropriate background check comparable to those
undergone by other non-management directors of the Company and interview with the Nominating and Governance Committee of the Board.
(b) Indemnification
and Advancement of Expenses; Compensation.
(i) In
connection with Section 1(a)(i), the Parties agree that Mr. Derycz shall be entitled to all applicable rights with respect
to indemnification and the advancement of expenses as provided under that certain Indemnification Agreement, dated as of June 22,
2015, by and among the Company and Mr. Derycz (the “Indemnification Agreement”), the Articles of Incorporation,
the Bylaws and/or Nevada law for all Pending Clams (as defined below). For the avoidance of doubt, the Parties acknowledge and agree
that nothing in this Agreement (inclusive of the foregoing and Section 6) shall be deemed to limit, abridge, amend, change
or otherwise modify in any way any right to indemnification or advancement of expenses under the Indemnification Agreement, the Articles
of Incorporation, the Bylaws and/or Nevada law with respect to any claims, losses or other actions Mr. Derycz is unaware of as of
or which the Company and/or Mr. Derycz are made aware of after the Effective Date, in each case, related to, arising out of or in
connection with Mr. Derycz’s prior service as a director or officer of, or in any other position with, the Company or
any of its Affiliates (the “Preserved Indemnification Rights”), which remain in full force and effect in accordance
with their terms, as applicable, and consistent with the rights of other former directors and officers of the Company.
(ii) Each
of the Parties acknowledges that all known, pending claims, losses or other actions related to, arising out of or in connection with
Mr. Derycz’s prior service as a director or officer of, or in any other position with, the Company of any of its Affiliates,
as well as Mr. Derycz’s claims with respect to indemnification and the advancement of expenses, in each case as of the
Effective Date, are included in Exhibit A (the “Pending Claims”).
(iii) Upon
execution of the release set forth in Exhibit A of the Employment Agreement, Mr. Derycz shall receive his present base compensation
paid through March 28, 2024 (the end of his term as defined in that certain Amended and Restated Executive Employment Agreement,
dated as of March 29, 2021, by and between the Company and Mr. Derycz), in accordance with the Company’s regular payroll
practices. Such base compensation shall be paid in ordinary course, less all relevant taxes and other withholdings, on each regular payroll
date commencing on September 15, 2023 and ending on March 31, 2024. In addition, Mr. Derycz shall be entitled to receive
his remaining bonus in respect of the 2023 fiscal year in the amount of $17,055, such amount to be paid in one lump sum on the first
payroll date following the Effective Date, and, as of the Effective Date, shall receive immediate vesting on his 60,278 shares of Common
Stock. The Parties acknowledge and agree that Mr. Derycz shall not be entitled to any other compensation for services performed
for the Company prior to the Effective Date. During such time as Mr. Derycz continues to be paid severance by the Company, he will
work in good faith with the Company to assist in the transition of any items that require transition by nature of his departure from
the Company.
(c) Board
Policies and Procedures. Each Party acknowledges that the New Director, upon appointment to the Board, shall be governed by all of
the same policies, processes, procedures, codes, rules, standards and guidelines applicable to members of the Board, including, without
limitation, the Company’s Code of Ethical Conduct and any other policies on stock ownership, public disclosures, legal compliance
and confidentiality (collectively, the “Company Policies”) and all applicable rules and regulations of The Nasdaq
Stock Market (including, without limitation, its independence standards), and will be required to strictly adhere to the Company’s
policies on confidentiality imposed on all members of the Board. The Company agrees that upon appointment to the Board, the New Director
shall receive (i) the same benefits of director and officer insurance as all other non-management directors on the Board, (ii) the
same compensation for his or her service as a director as the compensation received by other non-management directors on the Board and
(iii) such other benefits on the same basis as all other non-management directors on the Board.
2. Withdrawal
of Proxy Contest and Related Matters. Concurrently with and effective upon execution of this Agreement, the Investor Group shall
(a) irrevocably withdraw or cause the irrevocable withdrawal of the Notice (with this Agreement deemed to evidence such withdrawal)
and any and all related materials and notices submitted to the Company in connection therewith or related thereto, and (b) cease
and take no further action in connection with the solicitation of proxies in connection with the Notice and/or the 2023 Annual Meeting
(other than in connection with such withdrawal or Section 12 hereof, and it being understood and agreed that each member of the
Investor Group is required to vote his or its Voting Securities beneficially owned as of the record date with respect to the 2023 Annual
Meeting, subject to the provisions of this Agreement).
3. Voting.
From the Effective Date until the Termination Date (the “Standstill Period”), each member of the Investor Group agrees
that he or it will, and shall cause his or its respective Affiliates to, appear in person or by proxy at each annual or special meeting
of stockholders of the Company (including, without limitation, any adjournments or postponements thereof and any meetings which may be
called in lieu thereof), whether such meeting is held at a physical location or virtually by means of remote communications, and will
vote (or, in connection with any actions taken by written consent of stockholders, execute a consent with respect to) all Voting Securities
beneficially owned by it in accordance with the Board’s recommendations with respect to (a) the election, removal or replacement
of any director and (b) any other proposal to be submitted to the stockholders of the Company by either the Company or any stockholder
of the Company; provided, however, that if Institutional Shareholder Services Inc. (“ISS”) and Glass
Lewis & Co. LLC (“Glass Lewis”) (including, without limitation, any successor thereto) issue a voting recommendation
that differs from the Board’s recommendation with respect to any proposal submitted to stockholders at a stockholder meeting (other
than with respect to the election, removal or replacement of directors), each member of the Investor Group shall be permitted to vote
in accordance with ISS’s and Glass Lewis’s recommendation; provided, further, that each member of the Investor
Group shall be permitted to vote in his or its sole discretion on any proposal of the Company in respect of any Extraordinary Transaction.
4. Mutual
Non-Disparagement.
(a) During
the Standstill Period, each member of the Investor Group agrees that neither he or it nor any of his or its Affiliates or controlled
Associates shall make any public statement, or take any action that is intended to result in a public statement, that constitutes an
ad hominem attack on, or otherwise is critical, negative towards or derogatory or otherwise disparages, defames or damages the
reputation of the Company or its Affiliates or any of the Company’s past or current directors, officers or employees. For the avoidance
of doubt, the Investor Group shall avoid making statements of the nature described herein to employees of the Company as well.
(b) During
the Standstill Period, neither the Company nor any of its Affiliates or controlled Associates shall make any public statement, or take
any action that is intended to result in a public statement, that constitutes an ad hominem attack on, or otherwise is critical,
negative towards or derogatory or otherwise disparages, defames or damages the reputation of any member of the Investor Group or his
or its Affiliates, or any member of the Investor Group’s past or current directors, officers or employees. For the avoidance of
doubt, the Company shall avoid making statements of the nature described herein to employees of any member of the Investor Group as well.
(c) Notwithstanding
the foregoing, nothing in this Section 4 or elsewhere in this Agreement shall prohibit any Party from making any statement
or disclosure required under the federal securities laws or other applicable laws (including, without limitation, to comply with any
subpoena or other legal process from any governmental or regulatory authority with competent jurisdiction over the relevant Party hereto)
or stock exchange regulations, or from making any truthful statement to any other Party or any of its Representatives so long as, and
to the extent that, such statement is not in breach of any confidentiality obligations such Party may have.
(d) The
limitations set forth in Sections 4(a) or (b), as applicable, shall not prevent any Party from responding to
any public statement made by the other Party of the nature described in Sections 4(a) or (b), as applicable,
if such statement by the other Party was made in breach of this Agreement.
5. No
Litigation. During the Standstill Period, each Party covenants and agrees that it shall not, alone or in concert with others, initiate
or pursue, any lawsuit, claim or proceeding (including, without limitation, with respect to any member of the Investor Group, commencing
or knowingly encouraging or supporting any derivative action in the name of the Company or any class action against the Company or any
of its officers or directors, in each case with the intent of circumventing any terms of this Agreement) before any court or governmental,
administrative or regulatory body (collectively, a “Legal Proceeding”) against (a) with respect to any member
of the Investor Group, the Company or any of its Representatives (solely in the context of their representation of the Company in connection
with the subject matter of this Agreement), and (b) with respect to the Company, each member of the Investor Group or any of his
or its Representatives (solely in the context of their representation of any member of the Investor Group in connection with the subject
matter of this Agreement); provided, however, that nothing in this Agreement (including, without limitation, the foregoing
and Section 6) shall prevent (w) any Party or any of its Representatives from responding to oral questions, interrogatories,
requests for information or documents, subpoenas, civil investigative demands or similar processes (a “Legal Requirement”)
in connection with any Legal Proceeding if such Legal Proceeding has not been initiated by, or on behalf of, such Party, (x) litigation
by any Party to enforce the provisions of this Agreement, (y) counterclaims with respect to any proceeding initiated by a Party
in breach of this Agreement and (z) the exercise of statutory appraisal rights; provided, further, that in the event
that such Party or any of its Representatives receives such Legal Requirement, such Party shall, unless prohibited by applicable law,
give prompt written notice of such Legal Requirement to the other Party.
6. Releases.
(a) As
of the Effective Date, each member of the Investor Group, on behalf of themselves and each member of the Investor Released Group, permanently,
fully and completely releases, acquits and discharges the Company, and the Company’s subsidiaries, joint ventures and partnerships,
successors, assigns, officers, directors, partners, members, managers, principals, predecessor or successor entities, agents, employees,
stockholders, auditors, advisors, consultants, attorneys, insurers, heirs, executors, administrators, successors and assigns of any such
person (in each case, in their capacities as such) (collectively, the “Company Released Group”), jointly or severally,
of and from any and all claims, demands, damages, causes of action, debts, liabilities, controversies, judgments, and suits of every
kind and nature whatsoever, direct or derivative, foreseen, unforeseen, known or unknown, that any member of the Investor Group has had,
now has, or may have against any of the Company and/or the Company Released Group arising out of or in any way related to any member
of the Investor Group’s involvement with the Company, including without limitation, employment at the Company or ownership of securities
of the Company, collectively, jointly or severally, at any time prior to and including the Effective Date (the “Investor Group
Release”).
(b) As
of the Effective Date, the Company, on behalf of itself and each member of the Company Released Group, permanently, fully and completely
releases, acquits and discharges each member of the Investor Group, and the Investor Group’s subsidiaries, joint ventures and partnerships,
successors, assigns, officers, directors, partners, members, managers, principals, predecessor or successor entities, agents, employees,
stockholders, auditors, advisors, consultants, attorneys, insurers, heirs, executors, administrators, successors and assigns of any such
person (in each case, in their capacities as such) (collectively, the “Investor Released Group”), jointly or severally,
of and from any and all claims, demands, damages, causes of action, debts, liabilities, controversies, judgments, and suits of every
kind and nature whatsoever, direct or derivative, foreseen, unforeseen, known or unknown, that the Company has had, now has, or may have
against any member of the Investor Group and/or the Investor Released Group arising out of or in any way related to any member of the
Investor Group’s involvement with the Company, including without limitation, employment at the Company or ownership of securities
of the Company, collectively, jointly or severally, at any time prior to and including the Effective Date (the “Company Release”
and together with the Investor Group Release, the “Releases”).
(c) The
Parties each acknowledge that as of the time of the Effective Date, the Parties may have claims against one another that a Party does
not know or suspect to exist in his or its favor, including, without limitation, claims that, had they been known, might have affected
the decision to enter into this Agreement, or to provide the releases set forth in this Section 6. In connection with
such any such claims, the Parties agree that they intend to waive, relinquish, and release any and all provisions, rights, and benefits
any state or territory of the United States or other jurisdiction that purports to limit the application of a release to unknown claims,
or to facts unknown at the time the release was entered into. In connection with this waiver, the Parties acknowledge that they, or any
of them, may (including after the Effective Date) discover facts in addition to or different from those known or believed by them to
be true with respect to the subject matter of the releases set forth in this Section 6, but it is the intention of the
Parties to complete, fully, finally, and forever compromise, settle, release, discharge, and extinguish any and all claims that they
may have one against another, known or unknown, suspected or unsuspected, contingent or absolute, accrued or unaccrued, apparent or unapparent,
that now exist or previously existed, without regard to the subsequent discovery of additional or different facts. The Parties acknowledge
that the foregoing waiver is a key, bargained-for element to this Agreement and the Releases that are part of it.
(d) The
Releases provided for in this Section 6 are intended to be broad, and this breadth is a bargained-for feature of this Agreement.
Notwithstanding anything to the contrary herein, the Releases provided for in this Section 6 shall not apply to (i) the
Preserved Indemnification Rights and (ii) any rights or duties under this Agreement or (iii) any claims or causes of action
that any Party may have for the breach or enforcement of any provision of this Agreement.
7. Standstill.
(a) During
the Standstill Period, each member of the Investor Group agrees that he or it shall not, and shall cause his or its Affiliates and controlled
Associates not to, directly or indirectly:
(i) acquire,
offer or seek to acquire, agree to acquire, or acquire rights or options to acquire (except by way of stock dividends or other distributions
or offerings made available to holders of Voting Securities generally on a pro rata basis or pursuant to an Extraordinary Transaction),
whether by purchase, tender or exchange offer, through the acquisition of control of another person, by joining a group, through swap
or hedging transactions or otherwise, any securities of the Company (other than through a broad-based market basket or index), any rights
decoupled from the underlying securities of the Company, or any derivative securities, contracts or instruments in any way related to
the price of shares of Common Stock, or any assets or liabilities of the Company;
(ii) make
any public announcement or proposal with respect to, or publicly offer or propose, (A) any form of business combination or acquisition
or other transaction relating to all or substantially all of the assets or securities of the Company or any of its subsidiaries, (B) any
form of restructuring, recapitalization or similar transaction with respect to the Company or any of its subsidiaries or (C) any
form of tender or exchange offer for Voting Securities, whether or not such transaction involves a Change of Control; it being understood
that the foregoing shall not prohibit any member of the Investor Group or his or its Affiliates or Associates from (x) selling or
tendering his or its shares of Common Stock, and otherwise receiving consideration, pursuant to any such transaction or (y) voting
on any such transaction in accordance with Section 3;
(iii) engage
in, or knowingly assist in the engagement in (including, without limitation, engagement by use of or in coordination with a universal
proxy card) any solicitation of proxies or written consents to vote any Voting Securities, or conduct any type of binding or nonbinding
referendum with respect to any Voting Securities, or participate in any other way, directly or indirectly, in any solicitation of proxies
(or written consents) with respect to, or from the holders of, any Voting Securities, or otherwise become a “participant”
in a “solicitation,” as such terms are defined in Instruction 3 of Item 4 of Schedule 14A and Rule 14a-1 of Regulation
14A, respectively, under the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “Exchange
Act”), to vote any securities of the Company (including, without limitation, by initiating or knowingly encouraging or participating
in any “withhold” or similar campaign), in each case, other than in a manner that is consistent with the Board’s recommendation
on a matter;
(iv) advise
or knowingly encourage any person with respect to the voting of (or execution of a written consent in respect of) or disposition of any
securities of the Company, other than in a manner that is consistent with the Board’s recommendation on a matter;
(v) other
than in open market sale transactions whereby the identity of the purchaser is not known, sell, offer or agree to sell directly or indirectly,
through swap or hedging transactions or otherwise, the securities of the Company or any rights decoupled from the underlying securities
held by the Investor Group to any Third Party with a known history of activism or known plans to engage in activism (in each case, known
to the seller); provided that with respect to each of Bristol Investment Fund, Ltd., Bristol Capital Advisors, LLC and Mr. Kessler,
the foregoing shall not apply to or restrict any sale transaction in the securities of the Company to any Third Party who has filed a
Schedule 13G or 13D with respect to the Company on or prior to the Effective Date;
(vi) intentionally
take any action in support of or make any proposal or request that constitutes or would result in: (A) advising, replacing or influencing
any director or the management of the Company, including, without limitation, any plans or proposals to change the number or term of
directors or to fill any vacancies on the Board, (B) any material change in the capitalization, stock repurchase programs and practices
or dividend policy of the Company, (C) any other material change in the Company’s management, business or corporate structure,
(D) seeking to have the Company waive or make amendments or modifications to the Bylaws or the Articles of Incorporation, or other
actions that could reasonably be expected to impede or facilitate the acquisition of control of the Company by any person, (E) causing
a class of securities of the Company to be delisted from, or to cease to be authorized to be quoted on, any securities exchange, or (F) causing
a class of securities of the Company to become eligible for termination of registration pursuant to Section 12(g)(4) of the
Exchange Act (in each case except as otherwise permitted by Section 1 or Section 3 hereof);
(vii) communicate
with stockholders of the Company or others pursuant to Rule 14a-1(l)(2)(iv) under the Exchange Act (other than in connection
with an Extraordinary Transaction);
(viii) call
or seek to call, or request the call of, alone or in concert with others, any meeting of stockholders, whether or not such a meeting
is permitted by the Bylaws, including, without limitation, a “town hall meeting”;
(ix) deposit
any Voting Securities in any voting trust or subject any Voting Securities to any arrangement or agreement with respect to the voting
of any Voting Securities (other than (A) any such voting trust, arrangement or agreement solely among the Investor Group and its
Affiliates that is otherwise in accordance with this Agreement or (B) customary brokerage accounts, margin accounts, prime brokerage
accounts and the like);
(x) knowingly
encourage or advise any person to submit nominations in furtherance of a “contested solicitation” for the election or removal
of directors with respect to the Company, or knowingly encourage or advise any person to take any other action with respect to the election
or removal of any directors;
(xi) form,
join or in any other way participate in any “group” (within the meaning of Section 13(d)(3) of the Exchange Act)
with respect to any Voting Security; provided, however, that nothing herein shall limit the ability of an Affiliate of
a member of the Investor Group to join or in any way participate in a “group” solely among members of the Investor Group
and their Affiliates, so long as any such Affiliate agrees to be subject to, and bound by, the terms and conditions of this Agreement
and, if required under the Exchange Act, files a Schedule 13D or an amendment thereof, as applicable, within two (2) business days
after disclosing that the Investor Group has formed a group with such Affiliate;
(xii) demand
a copy of the Company’s list of stockholders or its other books and records or make any request pursuant to Rule 14a-7 under
the Exchange Act or under any statutory or regulatory provisions of Nevada providing for stockholder access to books and records (including,
without limitation, lists of stockholders) of the Company;
(xiii) make
any request or submit any proposal to amend or waive the terms of this Section 7 other than through non-public communications
with the Company that are not reasonably expected to trigger public disclosure obligations for any Party; or
(xiv) enter
into any discussions, negotiations, agreements or understandings with any person to take any action the Investor Group is prohibited
from taking pursuant to this Section 7, or advise, knowingly encourage or seek to persuade any person to take any action
or make any statement the Investor Group is prohibited from taking or making pursuant to this Section 7.
(b) Notwithstanding
anything to the contrary contained in Section 7(a) or elsewhere in this Agreement, (i) the Investor Group shall
not be prohibited or restricted from: (A) communicating privately with members of the Board or officers of the Company regarding
any matter in a manner consistent with communications that may be reasonably made by all stockholders of the Company, so long as such
communications are not intended to, and would not reasonably be expected to, require any public disclosure of such communications by
any Party; (B) taking any action necessary to comply with any law, rule or regulation or any action required by any governmental
or regulatory authority or stock exchange that has, or may have, jurisdiction over the Investor Group; provided, that an intentional
breach by any member of the Investor Group of this Agreement is not the cause of the applicable requirement; or (C) communicating
with stockholders of the Company and others in a manner that does not otherwise violate this Agreement and (ii) the provisions of
Section 7(a) shall not limit in any respect the actions of any director of the Company in his or her capacity as such,
recognizing that such actions are subject to such director’s fiduciary duties to the Company and its stockholders and the Company
Policies (it being understood and agreed that no member of the Investor Group shall take any actions to indirectly violate any provision
of Section 7(a)). The provisions of Section 7(a) shall also not prevent any member of the Investor Group
from freely voting his or its shares of Common Stock (except as otherwise provided in Section 3). Additionally, notwithstanding
anything to the contrary contained in Section 7(a) or elsewhere in this Agreement, Mr. Derycz shall be permitted
to transfer to Bristol Capital Advisors, LLC, and Bristol Capital Advisors, LLC shall be permitted to receive from Mr. Derycz, up
to 20,000 shares of Common Stock on or prior to December 31, 2023, which transfer shall not constitute a Proposed Sale or be subject
to the Right of First Refusal (each as defined below) under Section 8.
(c) Nothing
in this Agreement shall limit in any respect the actions or rights of any director of the Company (including, for the avoidance of doubt,
the New Director) under applicable law in his or her capacity as such. Without limiting the foregoing, the New Director shall have the
same (i) access to members of management as every other director and (ii) rights as every other director to access the books
and records of the Company and to make information requests of management in order to facilitate these rights.
8. Right
of First Refusal.
(a) During
the Standstill Period, Mr. Derycz hereby grants the Company an exclusive option (the “Right of First Refusal”)
to purchase any securities of the Company, or have its third-party investor relations firm, on behalf of the Company, identify a purchaser
for such securities, offered by Mr. Derycz that Mr. Derycz proposes to transfer in a single transaction or series of related
transactions in a privately negotiated transaction (any such proposed transfer, a “Proposed Sale”). A Proposed Sale
shall not include (i) any open market sale transactions or (ii) any transfer from Mr. Derycz to an Affiliate, Associate
or an immediate family member (solely to extent in accordance and consistent with Mr. Derycz’s previous estate planning practices);
provided, however, that Mr. Derycz shall (x) cause any such Affiliates, Associates or immediate family member
to comply with this Section 8 and (y) be responsible for any breach of this Section 8 by any such Affiliate,
Associate or immediate family member that results from actions by such Affiliate, Associate or immediate family member, which, if taken
by Mr. Derycz, would violate this Section 8.
(b) Before
Mr. Derycz may effect a Proposed Sale, Mr. Derycz shall provide written notice (the “ROFR Notice”) to the
Company stating (i) Mr. Derycz’s bona fide intention to transfer shares in a Proposed Sale, (ii) the number of shares
to be transferred to such transferee (the “Transfer Shares”), and (iii) the bona fide cash price or other consideration
for which Mr. Derycz proposes to transfer such shares (the “Offer Price”). Mr. Derycz shall be permitted
to withdraw any ROFR Notice at any time prior to receipt of notice of the Company’s intent to exercise the Right of First Refusal.
(c) The
Company shall have five (5) business days from the time of its receipt of the ROFR Notice to give written notice to Mr. Derycz
of its intent to exercise its Right of First Refusal to acquire, or have its third-party investor relations firm, on behalf of the Company,
identify a purchaser for some or all of such Transfer Shares (the “Exercise Notice”). The Company shall have five
(5) business days after the delivery of a timely Exercise Notice to tender the Offer Price for such shares to Mr. Derycz. Upon
receipt of the Offer Price, Mr. Derycz shall take all actions necessary to convey title to such Transfer Shares to the Company or
its assignee, and Mr. Derycz shall have no further rights to such Transfer Shares.
(d) If
the Company affirmatively declines or fails to properly exercise its Right of First Refusal or fails to provide a timely Exercise Notice,
Mr. Derycz shall be free to sell the Transfer Shares; provided, however, that as a condition to such sale, the transferee
shall take such Transfer Shares; provided, further, that such Proposed Sale shall be consummated within 30 days after receipt
of the ROFR Notice by the Company and shall be consummated on terms no less favorable to Mr. Derycz than the terms proposed in the
ROFR Notice. To the extent that such Proposed Sale is not consummated within this time period, Mr. Derycz will be obligated to send
a new ROFR Notice to the Company, and the provisions and procedures described in this Section 8 shall continue to apply.
(e) The
Parties agree that the Company may assign the Right of First Refusal to one or more purchasers identified by the Company’s third-party
investor relations firm, as named in the Exercise Notice.
9. Representations
and Warranties of the Company. The Company represents and warrants to the Investor Group that (a) the Company has the corporate
power and authority to execute this Agreement and to bind it thereto, (b) this Agreement has been duly and validly authorized, executed
and delivered by the Company, constitutes a valid and binding obligation and agreement of the Company, and is enforceable against the
Company in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance or similar laws generally affecting the rights and remedies of creditors and subject to general equity
principles and (c) the execution, delivery and performance of this Agreement by the Company does not and will not violate or conflict
with (i) any law, rule, regulation, order, judgment or decree applicable to it, or (ii) result in any breach or violation of
or constitute a default (or an event which with notice or lapse of time or both could become a default) under or pursuant to, or result
in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational
document, or any material agreement, contract, commitment, understanding or arrangement to which the Company is a party or by which it
is bound. In addition to the foregoing, the Company represents and warrants to the Investor Group that, other than the Pending Claims
listed on Exhibit A, the Company and its Representatives are not aware of any pending claims against Mr. Derycz related
to, arising out of or in connection to his prior service as a director or officer of, or in any other position with, the Company or any
of its Affiliates.
10. Representations
and Warranties of the Investor Group. Each member of the Investor Group represents and warrants to the Company solely for and on
behalf of himself or itself that (a) this Agreement has been duly and validly authorized, executed and delivered by such member
of the Investor Group, and constitutes a valid and binding obligation and agreement of such member of the Investor Group, enforceable
against such member of the Investor Group in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights and remedies of creditors
and subject to general equity principles, (b) the Investor Group beneficially owns an aggregate of 5,921,930 shares of Common Stock,
(c) the signatory for such member of the Investor Group has the power and authority to execute this Agreement and any other documents
or agreements entered into in connection with this Agreement on behalf of himself or itself and the applicable member of the Investor
Group associated with that signatory’s name, and to bind such member of the Investor Group to the terms hereof and thereof, (d) the
execution, delivery and performance of this Agreement by such member of the Investor Group does not and will not violate or conflict
with (i) any law, rule, regulation, order, judgment or decree applicable to it, or (ii) result in any breach or violation of
or constitute a default (or an event which with notice or lapse of time or both could become a default) under or pursuant to, or result
in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational
document or any material agreement, contract, commitment, understanding or arrangement to which such member is a party or by which it
is bound, (e) such member of the Investor Group shall not seek, and such member of the Investor Group acknowledges that he or it
will not have the right to receive, confidential information concerning the Company from the New Director, and (f) such member of
the Investor Group is not and will not become party to any agreement, arrangement or understanding (whether written or oral) with the
New Director with respect to such person’s service as a director on the Board. In addition to the foregoing, Mr. Derycz represents
and warrants to the Company that, other than those Pending Claims listed on Exhibit A, Mr. Derycz is not aware of any
claims for indemnification or advancement of his expenses related to, arising out of or in connection to his prior service as a director
or officer of, or in any other position with, the Company or any of its Affiliates.
11. No
Other Discussions or Arrangements. Each member of the Investor Group represents and warrants that, as of the Effective Date, except
as publicly disclosed in his or its SEC filings or otherwise specifically disclosed to the Company in writing prior to the Effective
Date, such member of the Investor Group (a) does not own, of record or beneficially, any Voting Securities or any securities convertible
into, or exchangeable or exercisable for, any Voting Securities and (b) has not entered into, directly or indirectly, any agreements
or understandings with any person (other than his or its own Representatives) with respect to any potential transaction involving the
Company or the voting or disposition of any securities of the Company.
12. Press
Release and SEC Filings.
(a) Promptly
following the Effective Date, the Company shall issue a press release in substantially the form attached hereto as Exhibit B
(the “Press Release”) announcing certain terms of this Agreement. Neither the Company nor the Investor Group shall
make or cause to be made, and the Company and the Investor Group shall cause their respective Affiliates and controlled Associates not
to make or cause to be made, any public announcement or statement with respect to the subject matter of this Agreement that is contrary
to the statements made in the Press Release or the terms of this Agreement, except as required by law or the rules of any stock
exchange or with the prior written consent of the other Party.
(b) The
Company shall file with the SEC a Current Report on Form 8-K reporting its entry into this Agreement and including this Agreement
as an exhibit thereto (the “Form 8-K”). The Form 8-K shall be consistent with the terms of this Agreement.
The Company shall provide the Investor Group with a reasonable opportunity to review and comment on the Form 8-K prior to the filing
with the SEC and consider in good faith any such comments of the Investor Group.
(c) No
later than two (2) business days following the Effective Date, the Investor Group shall file with the SEC an amendment to that certain
Schedule 13D, filed with the SEC on September 17, 2013, as amended (the “Investor Group Schedule 13D”), in compliance
with Section 13 of the Exchange Act reporting its entry into this Agreement (the “Investor Group Schedule 13D Amendment”).
The disclosures in the Investor Group Schedule 13D Amendment relating to this Agreement shall be consistent with the terms of this Agreement.
The Investor Group shall provide the Company with a reasonable opportunity to review and comment on the Investor Group Schedule 13D Amendment
prior to it being filed with the SEC and consider in good faith any such comments of the Company.
13. Term;
Termination. The term of this Agreement shall commence on the Effective Date and shall remain in effect until the date that is the
earlier of (a) thirty (30) days after the conclusion of the 2024 Annual Meeting, and (b) December 30, 2024 (such date,
the “Termination Date”); provided, that (c) the Investor Group may earlier terminate this Agreement if
the Company commits a material breach of its obligations under this Agreement that (if capable of being cured) is not cured within fifteen
(15) days after the Company’s receipt of written notice specifying the material breach from the Investor Group, and (d) the
Company may earlier terminate this Agreement if any member of the Investor Group commits a material breach of this Agreement that (if
capable of being cured) is not cured within fifteen (15) days after the Investor Group’s receipt of written notice thereof from
the Company specifying the material breach. Notwithstanding the foregoing, the provisions of Section 15 through Section 25
shall survive the termination of this Agreement. Termination of this Agreement shall not relieve any Party from its responsibilities
in respect of any breach of this Agreement prior to such termination.
14. Expenses.
Each Party shall be responsible for its own fees and expenses in connection with the negotiation and execution of this Agreement and
the transactions contemplated hereby; provided, however, that the Company shall pay to the Investor Group an amount not
to exceed $100,000 in the aggregate, (a) in exchange for the Investor Group Release from the Investor Group set forth in Section 6(a),
in connection with the Pending Claims, and (b) as reimbursement for reasonable, documented out-of-pocket fees and expenses incurred
in connection with the matters related to the 2023 Annual Meeting, including, without limitation, the negotiation and execution of this
Agreement and the transactions contemplated hereby.
15. Governing
Law; Jurisdiction. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Nevada
without giving effect to any choice or conflict of law provision or rule that would cause the application of laws of any jurisdiction
other than those of the State of Nevada. Each Party irrevocably (a) agrees that it shall bring any suit, action, or other proceeding
in respect of any claim arising out of or related to this Agreement (each, an “Action”) exclusively in any state
or federal court located in Clark County, Nevada or another federal or state court of competent jurisdiction, (b) waives any jurisdictional
defenses (including, without limitation, personal jurisdiction and venue) to any such Action, (c) waives any objection that such
courts identified in clause (a) are an inconvenient forum or do not have jurisdiction over any Party and (d) agrees
that service of process upon such Party in any such Action shall be effective if notice is given in accordance with Section 19
of this Agreement. Each Party agrees that a final judgment in any Action brought in the courts identified in clause (a) shall
be conclusive and binding upon each of the Parties and may be enforced in any other courts, the jurisdiction of which each of the Parties
is or may be subject, by suit upon such judgment.
16. Waiver
of Jury Trial. EACH PARTY TO THIS AGREEMENT ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT
IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES TO THE FULLEST
EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING
TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (A) NO
REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING
WAIVER IN THE EVENT OF A LEGAL ACTION, (B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES
THIS WAIVER VOLUNTARILY, AND (D) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS
AND CERTIFICATIONS IN THIS SECTION 16.
17. Specific
Performance. Each of the Parties acknowledges and agrees that irreparable injury to the other Parties may occur in the event any
of the provisions of this Agreement are not performed in accordance with their specific terms or are otherwise breached and that such
injury may not be adequately compensable by the remedies available at law (including, without limitation, the payment of money damages).
It is accordingly agreed that each of the Parties (the “Moving Party”) shall be entitled to seek specific enforcement
of, and injunctive or other equitable relief as a remedy for any such breach or to prevent any violation or threatened violation of,
the terms hereof, and the other Parties will not take action, directly or indirectly, in opposition to the Moving Party seeking such
relief on the grounds that any other remedy or relief is available at law or in equity. The Parties further agree to waive any requirement
for the security or posting of any bond in connection with any such relief. The remedies available pursuant to this Section 17
shall not be deemed to be the exclusive remedies for a breach of this Agreement but shall be in addition to all other remedies available
at law or equity.
18. Certain
Definitions. As used in this Agreement:
(a) “Affiliate”
shall mean any “Affiliate” as defined in Rule 12b-2 promulgated by the SEC under the Exchange Act, including, without
limitation, persons who become Affiliates subsequent to the Effective Date;
(b) “Articles
of Incorporation” shall mean the Articles of Incorporation of the Company, as may be amended, corrected, or amended and restated
from time to time;
(c) “Associate”
shall mean any “Associate” as defined in Rule 12b-2 promulgated by the SEC under the Exchange Act, including, without
limitation, persons who become Associates subsequent to the Effective Date;
(d) “beneficial
owner,” “beneficial ownership” and “beneficially own” shall have the same meanings as
set forth in Rule 13d-3 promulgated by the SEC under the Exchange Act;
(e) “business
day” shall mean any day other than a Saturday, Sunday or day on which the commercial banks in the State of New York are authorized
or obligated to be closed by applicable law;
(f) “Bylaws”
shall mean the Amended and Restated Bylaws of the Company, as may be amended, corrected, or further amended and restated from time to
time;
(g) “Change
of Control” shall be deemed to have taken place if (i) any person is or becomes a beneficial owner, directly or indirectly,
of securities of the Company representing more than fifty percent (50%) of the equity interests and voting power of the Company’s
then-outstanding equity securities or (ii) the Company enters into a stock-for-stock transaction whereby immediately after the consummation
of the transaction the Company’s stockholders retain, directly or indirectly, less than fifty percent (50%) of the equity interests
and voting power of the surviving entity’s then-outstanding equity securities;
(h) “Extraordinary
Transaction” shall mean any equity tender offer, equity exchange offer, merger, acquisition, joint venture, business combination,
financing, recapitalization, reorganization, restructuring, disposition, distribution, or other transaction with a Third Party that,
in each case, would result in a Change of Control of the Company, liquidation, dissolution or other extraordinary transaction involving
a majority of its equity securities or a majority of its assets (determined on a consolidated basis), and, for the avoidance of doubt,
including, without limitation, any such transaction with a Third Party that is submitted for a vote of the Company’s stockholders;
(i) “person”
or “persons” shall mean any individual, corporation (including, without limitation, not-for-profit), general or limited
partnership, limited liability company, joint venture, estate, trust, association, organization or other entity of any kind, structure
or nature;
(j) “Representative”
shall mean a person’s Affiliates and Associates and its and their respective directors, officers, employees, partners, members,
managers, consultants, legal or other advisors, agents and other representatives; provided, that when used with respect to the
Company, “Representative” shall not include any non-executive employees or Mr. Derycz;
(k) “Third
Party” shall mean any person that is not (i) a party to this Agreement, (ii) a member of the Board, (iii) an
officer of the Company or (iv) an Affiliate of any Party; and
(l) “Voting
Securities” means the Common Stock and any other securities of the Company entitled to vote in the election of directors.
19. Notices.
All notices, requests, consents, claims, demands, waivers, and other communications hereunder shall be in writing and shall be deemed
to have been given: (a) when delivered by hand (with written confirmation of delivery), (b) one business day after being sent
by a nationally recognized overnight courier (receipt requested), (c) on the date sent by email (with confirmation of transmission)
if sent during normal business hours, and on the next business day if sent after normal business hours; or (d) on the third day
after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to
the respective Parties at the addresses set forth in this Section 19 (or to such other address that may be designated by
a Party from time to time in accordance with this Section 19).
If to the Company, to its address at: |
|
Research Solutions, Inc. |
10624 S. Eastern Avenue, Ste. A-614 |
Henderson, NV 89052 |
Attention: |
William Nurthen |
Email: |
bnurthen@reprintsdesk.com |
|
with a copy (which shall not constitute notice)
to: |
|
Vinson & Elkins L.L.P. |
1114 Avenue of the Americas, 32nd
Floor |
New York, NY 10036 |
Attention: |
Lawrence S. Elbaum |
|
Patrick Gadson |
Email: |
lelbaum@velaw.com |
|
pgadson@velaw.com |
If to the Investor Group, to each of their
addresses at: |
|
Peter Derycz |
2355 Westwood Boulevard, #739 |
Los Angeles, CA 90064 |
Email: |
trichicanovegano@gmail.com |
|
Bristol Capital Advisors, LLC |
555 Marin Street, Suite 140 |
Thousand Oaks, CA 91360 |
Attention: |
Paul L. Kessler |
|
Amy Wang |
Email: |
pkessler@bristolcompanies.net |
|
amy@bristolcompanies.net |
|
with a copy (which shall not constitute notice)
to: |
|
Olshan Frome Wolosky LLP |
1325 Avenue of the Americas |
New York, NY 10019 |
Attention: |
Kenneth Mantel |
|
Thomas Fleming |
Email: |
kmantel@olshanlaw.com |
|
tfleming@olshanlaw.com |
20. Entire
Agreement. This Agreement constitutes the sole and entire agreement of the Parties with respect to the subject matter contained herein,
and supersedes all prior and contemporaneous understandings, agreements, representations, and warranties, both written and oral, with
respect to such subject matter. This Agreement may be amended, modified or supplemented only by an agreement in writing signed by each
Party.
21. Severability.
If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability
shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other
jurisdiction.
22. Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed
to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, email or other means of electronic transmission
shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.
23. Assignment.
No Party may assign any of its rights or delegate any of its obligations hereunder without the prior written consent of the other Parties;
provided, that each Party may assign any of its rights and delegate any of its obligations hereunder to any person that acquires
substantially all of that Party’s assets, whether by stock sale, merger, asset sale or otherwise. Any purported assignment or delegation
in violation of this Section 23 shall be null and void. No assignment or delegation shall relieve the assigning or delegating
Party of any of its obligations hereunder. This Agreement is for the sole benefit of the Parties and their respective successors and
permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other person any legal or equitable
right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.
24. Waivers.
No waiver by any Party of any of the provisions of this Agreement shall be effective unless explicitly set forth in writing and signed
by the Party so waiving. No waiver by any Party shall operate or be construed as a waiver in respect of any failure, breach, or default
not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or after that
waiver. No failure to exercise, or delay in exercising, any right, remedy, power, or privilege arising from this Agreement shall operate
or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power, or privilege hereunder preclude
any other or further exercise thereof or the exercise of any other right, remedy, power, or privilege.
25. Interpretation.
Each of the Parties acknowledges that it has been represented by counsel of its choice throughout all negotiations that have preceded
the execution of this Agreement and that it has executed the same with the advice of said counsel. Each of the Parties and its respective
counsel cooperated and participated in the drafting and preparation of this Agreement and the documents referred to herein, and any and
all drafts relating thereto exchanged among the Parties shall be deemed the work product of all Parties and may not be construed against
any Party by reason of its drafting or preparation. Accordingly, any rule of law or any legal decision that would require interpretation
of any ambiguities in this Agreement against any Party that drafted or prepared it is of no application and is expressly waived by each
of the Parties hereto, and any controversy over interpretations of this Agreement shall be decided without regard to events of drafting
or preparation. The headings set forth in this Agreement are for convenience of reference purposes only and shall not affect or be deemed
to affect in any way the meaning or interpretation of this Agreement or any term or provision of this Agreement. In this Agreement, unless
a clear contrary intention appears, (a) the word “including” (in its various forms) means “including, without
limitation;” (b) the words “hereunder,” “hereof,” “hereto” and words of similar import
are references in this Agreement as a whole and not to any particular provision of this Agreement; (c) the word “or”
is not exclusive; (d) references to “Sections” in this Agreement are references to Sections of this Agreement unless
otherwise indicated; and (e) whenever the context requires, the masculine gender shall include the feminine and neuter genders.
(Remainder
of Page Intentionally Left Blank)
IN
WITNESS WHEREOF, the Parties have executed this Agreement to be effective as of the Effective Date.
|
The Company: |
|
|
|
RESEARCH SOLUTIONS, Inc. |
|
|
|
|
|
By: |
/s/ William Nurthen |
|
Name: |
William Nurthen |
|
Title: |
Chief Financial Officer |
|
|
|
|
|
THE INVESTOR GROUP: |
|
|
|
peter Derycz |
|
|
|
|
|
/s/ Peter Derycz |
|
|
|
BRISTOL INVESTMENT FUND, LTD. |
|
|
|
|
|
By: |
/s/ Paul Kessler |
|
Name: |
Paul Kessler |
|
Title: |
Director |
|
|
|
|
|
BRISTOL CAPITAL ADVISORS, LLC |
|
|
|
|
|
By: |
/s/ Paul Kessler |
|
Name: |
Paul Kessler |
|
Title: |
Manager and Chief Executive Officer |
|
|
|
|
|
PAUL KESSLER |
|
|
|
|
|
/s/ Paul Kessler |
Signature Page to
Cooperation Agreement
Exhibit A
Pending Claims
Exhibit B
Research Solutions Announces Cooperation Agreement
with Peter Derycz and Bristol Investment Fund, Ltd.
HENDERSON, Nev., September [ ], 2023
— Research Solutions, Inc. (NASDAQ: RSSS) (the “Company”), a trusted partner providing cloud-based
workflow solutions to accelerate research for R&D-driven organizations, announced today that it has entered into a cooperation agreement
(the “Cooperation Agreement”) with Peter Derycz, Bristol Investment Fund, Ltd., Bristol Capital Advisors, LLC and Paul
Kessler (collectively, the “Investor Group”), which collectively own 5,921,930 shares of the Company’s outstanding
common stock.
Under the terms of the Cooperation Agreement,
Mr. Derycz’s employment will be terminated without cause, and he will resign from the Company’s board of directors (the
“Board”) and all committees upon which he currently serves, and from any positions that he holds with the Company and any
of its subsidiaries. To fill the vacancy resulting from Mr. Dercyz’s departure, the Company will appoint an independent director
to the Board that is mutually agreed upon by the parties.
Additionally, the Investor Group has agreed to
withdraw its notice of intent to nominate director candidates for election at the Company’s 2023 Annual Meeting of Shareholders
(the “Annual Meeting”) and cease all solicitations of proxies and other activities in connection with the Annual Meeting.
During the term of the Cooperation Agreement, the Investor Group has also agreed to customary standstill provisions and voting commitments.
Further, the Company and the Investor Group have each agreed to a mutual general release of claims with respect to the other party.
“We are pleased to have reached this constructive
agreement with the Investor Group, which we believe is in the best interests of the Company and our shareholders,” said Roy W.
Olivier, Chief Executive Officer of the Company. “We look forward to putting this matter behind us and focusing on the continued
execution of our strategic plan.”
“The Investor Group is appreciative of
the collaborative approach taken by the Board in reaching this resolution,” said Peter Derycz. “We welcome the addition of
a new independent director that takes into account shareholder input, and believe that this addition can assist the Company in its commitment
to maximizing shareholder value.”
A copy of the Cooperation Agreement will be included
as an exhibit to the Company’s Current Report on Form 8-K, which will be filed with the U.S. Securities and Exchange Commission.
About Research Solutions
Research Solutions, Inc. (NASDAQ: RSSS)
provides cloud-based technologies to streamline the process of obtaining, managing, and creating intellectual property. Founded in 2006
as Reprints Desk, the company was a pioneer in developing solutions to serve researchers. Today, more than 70 percent of the top pharmaceutical
companies, prestigious universities, and emerging businesses rely on Article Galaxy, the company's SaaS research platform, to streamline
access to the latest scientific research and data with 24/7 customer support. For more information and details, please visit www.researchsolutions.com.
About Peter Derycz
Mr. Derycz is the Founder and Executive Chairman of Research
Solutions, Inc. and previously served as the President and Chief Executive Officer. Mr. Derycz has also founded and served
as the Chief Executive Officer and as a member of the board of directors of several other companies focused in the technology and end-user
sectors, and which provide access to published information to thousands of end-users around the world.
About Bristol Investment Fund Ltd.
Bristol seeks deep value investment opportunities in both publicly
traded and private companies, late stage pre-IPO companies (through private equity and/or bridge loans), and companies with valuation
metrics demonstrating significant potential for growth. Bristol has a 20+ year track record managing the fund's assets, employing an
investment team with several decades' worth of collective experience in investing in private equity and structured financing transactions
in public companies. Bristol evaluates the enterprise, financial condition, strength of management, strategy, governance, shareholder
constituency, and potential catalysts for growth in identifying those companies best suited for investment allocation.
Important Cautions Regarding Forward-Looking Statements
Certain statements in this press release may contain “forward-looking
statements” regarding future events and our future results. All statements other than statements of historical facts are statements
that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and
projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as “expects,”
“anticipates,” “targets,” “goals,”. “projects,” “intends,” "plans,”
“believes,” “seeks,” “estimates,” “endeavors,” “strives,” “may,”
or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned
that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict,
estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements.
Such risks and uncertainties include those factors described in the Company's most recent Annual Report on Form 10-K, as such may
be amended or supplemented by subsequent Quarterly Reports on Form 10-Q, or other reports filed with the Securities and Exchange
Commission. Examples of forward-looking statements in this release include statements regarding future personnel decisions, and the Company’s
prospects for growth. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements
are made only as of the date hereof, and the Company undertakes no obligation to publicly release the result of any revisions to these
forward-looking statements. For more information, please refer to the Company’s filings with the Securities and Exchange Commission.
Contact
Steven Hooser or John Beisler
Three Part Advisors
(214) 872-2710
shooser@threepa.com;
jbeisler@threepa.com
# # #
Exhibit 99.1
Research Solutions Announces Cooperation Agreement
with Peter Derycz and Bristol Investment Fund, Ltd.
HENDERSON, Nev., Sept. 18, 2023 /PRNewswire/
-- Research Solutions, Inc. (NASDAQ: RSSS) (the “Company”), a trusted partner providing cloud-based workflow solutions
to accelerate research for R&D-driven organizations, announced today that it has entered into a cooperation agreement (the “Cooperation
Agreement”) with Peter Derycz, Bristol Investment Fund, Ltd., Bristol Capital Advisors, LLC and Paul Kessler (collectively, the
“Investor Group”), which collectively own 5,921,930 shares of the Company’s outstanding common stock.
Under the terms of the Cooperation Agreement,
Mr. Derycz’s employment will be terminated without cause, and he will resign from the Company’s board of directors (the “Board”)
and all committees upon which he currently serves, and from any positions that he holds with the Company and any of its subsidiaries.
To fill the vacancy resulting from Mr. Dercyz’s departure, the Company will appoint an independent director to the Board that is
mutually agreed upon by the parties.
Additionally, the Investor Group has agreed to
withdraw its notice of intent to nominate director candidates for election at the Company’s 2023 Annual Meeting of Shareholders
(the “Annual Meeting”) and cease all solicitations of proxies and other activities in connection with the Annual Meeting.
During the term of the Cooperation Agreement, the Investor Group has also agreed to customary standstill provisions and voting commitments.
Further, the Company and the Investor Group have each agreed to a mutual general release of claims with respect to the other party.
“We are pleased to have reached this constructive
agreement with the Investor Group, which we believe is in the best interests of the Company and our shareholders,” said Roy W.
Olivier, Chief Executive Officer of the Company. “We look forward to putting this matter behind us and focusing on the continued
execution of our strategic plan.”
“The Investor Group is appreciative of
the collaborative approach taken by the Board in reaching this resolution,” said Peter Derycz. “We welcome the addition of
a new independent director that takes into account shareholder input, and believe that this addition can assist the Company in its commitment
to maximizing shareholder value.”
A copy of the Cooperation Agreement will be included
as an exhibit to the Company’s Current Report on Form 8-K, which will be filed with the U.S. Securities and Exchange Commission.
About Research Solutions
Research Solutions, Inc. (NASDAQ: RSSS) provides
cloud-based technologies to streamline the process of obtaining, managing, and creating intellectual property. Founded in 2006 as Reprints
Desk, the company was a pioneer in developing solutions to serve researchers. Today, more than 70 percent of the top pharmaceutical companies,
prestigious universities, and emerging businesses rely on Article Galaxy, the company's SaaS research platform, to streamline access
to the latest scientific research and data with 24/7 customer support. For more information and details, please visit www.researchsolutions.com.
About Peter Derycz
Mr. Derycz is the Founder and Executive Chairman
of Research Solutions, Inc. and previously served as the President and Chief Executive Officer. Mr. Derycz has also founded and served
as the Chief Executive Officer and as a member of the board of directors of several other companies focused in the technology and end-user
sectors, and which provide access to published information to thousands of end-users around the world.
About Bristol Investment Fund Ltd.
Bristol seeks deep value investment opportunities
in both publicly traded and private companies, late stage pre-IPO companies (through private equity and/or bridge loans), and companies
with valuation metrics demonstrating significant potential for growth. Bristol has a 20+ year track record managing the fund’s
assets, employing an investment team with several decades’ worth of collective experience in investing in private equity and structured
financing transactions in public companies. Bristol evaluates the enterprise, financial condition, strength of management, strategy,
governance, shareholder constituency, and potential catalysts for growth in identifying those companies best suited for investment allocation.
Important Cautions Regarding Forward-Looking
Statements
Certain statements in this press release may
contain “forward-looking statements” regarding future events and our future results. All statements other than statements
of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations,
estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words
such as “expects,” “anticipates,” “targets,” “goals,” “projects,” “intends,”
"plans,” “believes,” “seeks,” “estimates,” “endeavors,” “strives,”
“may,” or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers
are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult
to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking
statements. Such risks and uncertainties include those factors described in the Company's most recent Annual Report on Form 10-K, as
such may be amended or supplemented by subsequent Quarterly Reports on Form 10-Q, or other reports filed with the Securities and Exchange
Commission. Examples of forward-looking statements in this release include statements regarding future personnel decisions, and the Company’s
prospects for growth. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements
are made only as of the date hereof, and the Company undertakes no obligation to publicly release the result of any revisions to these
forward-looking statements. For more information, please refer to the Company’s filings with the Securities and Exchange Commission.
SOURCE Research Solutions, Inc.
For further information: Steven Hooser or John
Beisler, Three Part Advisors, (214) 872-2710, shooser@threepa.com; jbeisler@threepa.com
v3.23.3
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Research Solutions (NASDAQ:RSSS)
過去 株価チャート
から 4 2024 まで 5 2024
Research Solutions (NASDAQ:RSSS)
過去 株価チャート
から 5 2023 まで 5 2024